Please login to the form below

T-DM1

This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.

Immunotherapy and future directions in oncology

Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule

Latest news

EU backs Roche’s Kadcyla in breast cancer

Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its
Roche's Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer. Roche won approval in the US late last week for Kadcyla, its much-anticipated follow-up to breast cancer blockbuster Herceptin. ... The FDA has given the go-ahead to Kadcyla, formerly known as
Product updates from Japan

pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation
Roche delivers solid sales gain in 2012

Perjeta has been tipped as a future blockbuster, as has Herceptin follow-up trastuzumab emtansine ( T-DM1), which is filed in the US and Europe and expected to be on the
Genentech cancer drug delayed

Genentech is seeking approval for trastuzumab-DM1 (T-DM1) for use in patients with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies. ... T-DM1 links ImmunoGen's tumour-activated prodrug

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Roche names John Reed as new head of early research

investigational medicines, such as breast cancer drug T-DM1.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home-based Senior Medical Writer – Med Ed: Salary TBC

Programme/ Account Director - Healthcare PR - London: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Digital Health Specialist – Global Agency: Salary TBC

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Senior Account Manager, Medical Communications, London: Excellent package

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Scientific Director – Medical Communications: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Home based, Senior Medical Writer, Medical Communications: Excellent package

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Medical Writer: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Director – Healthcare Advertising – London: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Creative/ Medical Writer: Circa £35, 000 With Benefits

Home-based Medical Writer – Medical Education: Salary TBC

Health Consultant - Brand Comms: Competitive Salary

EU Head of Business Development and Client Service: Exceptional packge and bonus

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....